Related Experiment Videos
Development of novel substrates for tumor immunotherapy
Waleed S W Shalaby1, Heidi Yeh, Edward Woo
1Division of Gynecologic Oncology, University of Pennsylvania Medical Center, 3400 Spruce Street, First Floor Dulles, Suite 1000 Courtyard, Philadelphia, PA 19104, USA. wsalaby@mail.obgyn.upenn.edu
Summary
Acid-terminated polyglycolide microparticles (PG-MP) were engineered for immunotherapy. These microparticles successfully activated T cells and facilitated dendritic cell recruitment, demonstrating significant potential in a mouse tumor model.
Area of Science:
- Biomaterials Science
- Immunology
- Nanotechnology
Background:
- Polyglycolide microparticles (PG-MP) offer a versatile platform for drug delivery and immunotherapy.
- Surface modification of PG-MP allows for targeted biological applications, including immune cell activation and modulation.
- Developing effective cancer immunotherapies requires strategies to enhance T cell responses and recruit immune cells like dendritic cells.
Purpose of the Study:
- To prepare and characterize acid-terminated polyglycolide microparticles (PG-MP) as a versatile substrate.
- To functionalize PG-MP for either T cell activation via anti-CD3/anti-CD28 monoclonal antibodies (mAb) or sustained release of granulocyte-macrophage colony stimulating factor (GM-CSF).
- To evaluate the efficacy of functionalized PG-MP in a syngeneic mouse tumor model for prevention and regression.
Main Methods:
- Preparation of PG-MP with controlled size and surface chemistry (carboxylic acid groups).
- Surface modification of PG-MP for immobilization of anti-CD3/anti-CD28 mAb or encapsulation of GM-CSF.
- Assessment of T cell proliferation and cytokine production (IFN-gamma, IL-4) using flow cytometry.
- Evaluation of GM-CSF release kinetics and biological activity.
- In vivo testing in a Meth A fibrosarcoma mouse model for tumor prevention and regression, including analysis of dendritic cell infiltration.
Main Results:
- PG-MP were successfully prepared with a mean diameter of 56-57 microm and a carboxylic acid group concentration of 0.3 mmole/g.
- Immobilization of anti-CD3/anti-CD28 mAb on PG-MP induced significant T cell proliferation and IFN-gamma production.
- Sustained release of biologically active GM-CSF from modified microparticles was observed for up to 26 days.
- Co-injection of alpha-CD3/CD28-MP and GMCSF-MP completely prevented tumor implantation in mice.
- The combination therapy led to complete tumor regression in 4/7 mice and significant dendritic cell infiltration.
Conclusions:
- Acid-terminated PG-MP serve as an effective platform for developing dual-action immunotherapies.
- The dual-functionalized microparticles demonstrate potent anti-tumor activity by enhancing T cell responses and promoting dendritic cell recruitment.
- This approach holds promise for novel cancer treatment strategies leveraging biomaterial-based immunomodulation.